Isomorphic Labs closed a $2.1 billion Series B, one of the largest rounds in biotech history, to expand its AI-driven drug design engine and accelerate pipeline development. The round was led by Thrive Capital, with participation from Alphabet and Google’s GV, alongside additional investors including MGX, Temasek, CapitalG, and the UK government’s AI fund. The company said it will use the capital to scale its models and deploy its unified drug design engine, dubbed IsoDDE, with the funding framed around accelerating progress from target and candidate generation into clinical work. The size of the round signals renewed investor appetite for AI-first platforms that can translate computational discovery into development execution—an area where investors increasingly demand evidence of deployable biology, not just model performance.